Survodutide (5mg & 10mg)

Survodutide (BI 456906) is a synthetic dual GLP-1 and glucagon receptor agonist developed for metabolic research, supplied as a lyophilized powder for in-vitro laboratory research use. Purity specification: above 99% (HPLC-MS). Batch documentation is available on request. Supplied as lyophilized powder strictly for in-vitro research use only.

Survodutide (5mg & 10mg) serves as a research tool for examining the interplay between peptide signaling and metabolic endpoints in experimental designs.

Laboratory programs frequently validate Survodutide (5mg & 10mg) with HPLC purity checks and mass confirmation before assay work begins.

Survodutide (5mg & 10mg) is commonly included in metabolic research panels investigating appetite-regulating pathways and energy homeostasis in laboratory models.

This product is available in 5mg and 10mg. Each vial contains lyophilized peptide at the labeled quantity; wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only —not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Survodutide (5mg & 10mg). Summaries are provided for orientation only and reflect the cited sources.

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial^[1] —This randomised, double-blind, placebo-controlled phase 2 dose-finding trial evaluated the glucagon and GLP-1 receptor dual agonist survodutide in adults with obesity. The authors assessed weight reduction across multiple doses over 46 weeks of treatment. They reported dose-dependent weight loss, indicating that survodutide may be an effective investigational option for obesity. (The Lancet Diabetes & Endocrinology 2024)

Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial^[2] —This randomised clinical trial examined dose-response effects of survodutide on HbA1c and body weight in people with type 2 diabetes, compared with placebo and open-label semaglutide. The authors evaluated these endpoints over 16 weeks of treatment. The results indicated dose-dependent reductions in both glycaemic and weight parameters, supporting the dual agonist's potential in type 2 diabetes. (Diabetologia 2024)

Perspectives in weight control in diabetes - Survodutide^[3] —This review discusses perspectives on weight control in diabetes with the dual glucagon/GLP-1 receptor agonist survodutide. The authors examine its once-weekly dosing regimen and propose that activation of glucagon signaling may increase energy expenditure and thereby contribute to weight loss. They consider the implications of this mechanism for treating both type 2 diabetes and obesity. (Diabetes Research and Clinical Practice 2024)

References

1. le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. "Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial." The Lancet Diabetes & Endocrinology. 2024. sio-obesita.org/wp-content/uploads/2025/01/del-prete-2.pdf
2. Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. "Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial." Diabetologia. 2024. pmc.ncbi.nlm.nih.gov/articles/PMC10844353/pdf/125_2023_Article_605—
3. Klein T, Augustin R, Hennige AM. "Perspectives in weight control in diabetes - Survodutide." Diabetes Research and Clinical Practice. 2024. pubmed.ncbi.nlm.nih.gov/37330144/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.